UroGen Pharma (URGN) option IV into data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to UroGen Pharma (URGN) option IV into data
June 14, 2024 6:54 AM EDT
Ladenburg Thalmann analyst Matthew Kaplan raised the price target on UroGen Pharma (NASDAQ: URGN) to $53.50 (from $48.00) while maintaining a Buy rating.
The analyst comments "UroGen disclosed strong ENVISION 12-month DoR data (82.3%) at an investor event on June 13, 2024; Rolling NDA submission expected to complete by September 2024; Potential approval as soon as 1Q25, with priority... More
June 14, 2024 5:11 AM EDT
Goldman Sachs analyst Paul Choi reiterated a Neutral rating and $22.00 price target on UroGen Pharma (NASDAQ: URGN).
The analyst comments "Encouraging data for UGN-102 far exceeded expectations on 12-month durability of response; focus shifting to regulatory filing and subsequent launch execution. URGN is outperforming today (+41%... More
